Navigation Links
Quest PharmaTech Announces Results Showing its Photosensitizer, SL052, is an Effective Immuno-Stimulant when combined with Immunotherapy for the Removal of Solid Tumors
Date:3/4/2009

TSX Venture: QPT

EDMONTON, March 4 /PRNewswire-FirstCall/ - Quest PharmaTech Inc. (TSX-V: QPT), ("Quest" or the "Company") a pharmaceutical company developing and commercializing products for the treatment of cancer and dermatological conditions, today announced results from a study designed to investigate the effectiveness of its proprietary SL052 for photodynamic therapy (PDT) used in combination with immunotherapeutic agents in solid tumor animal models. The study, conducted by Dr. Mladen Korbelik at the BC Cancer Agency in Vancouver, demonstrated that SL052 increased the potency and effectiveness of immunotherapeutic agents when used in combination with SL052 PDT.

The results also confirmed that SL052 was an effective and well tolerated photosensitizer for PDT ablation of two highly tumorigenic, solid murine tumors. Further, the results demonstrated that photodynamic therapy generated direct local cytotoxicity and induced a systemic immune response, which could enhance its therapeutic effect on both primary tumors and metastases at distant sites.

The study tested several applications of SL052 and evaluated host recognition and immunological destruction of solid tumors. The results indicate the potential of SL052 PDT for use in combination with cancer vaccines to generate a superior immune response compared with vaccines alone. The study also revealed that SL052 PDT may be effectively combined with either single or multiple-complementary effectors of the host's immune response to substantially boost the frequency of permanent cures.

"The effects of immunotherapy can be amplified when combined with photodynamic therapy, potentially making immunophotodynamic therapy a superior systemic cancer treatment modality," said Thomas Woo, Vice President of Product Development at Quest.

SL052 is a non-toxic agent with broad potential to treat a variety of solid tumors using photodynamic (light activation) therapy or sonodynamic (ultrasound activation) therapy. Photodynamic therapy is applicable for superficial level solid tumors and sonodynamic therapy targets more deeply seated solid tumors.

"These results further define the therapeutic profile of SL052," stated Dr. Madi R. Madiyalakan, Chief Executive Officer at Quest. "While its activation through either photodynamic or sonodynamic therapy was already established, we now have a clear indication of its potential to act as either an immune response stimulator or as a cancer vaccine. Taken together, these characteristics of SL052 provide a new potential treatment modality for cancer therapy."

About SL052

SL052 is a member of Quest PharmaTech's SonoLight Portfolio with the potential to reduce or eliminate the side effects associated with currently available cancer treatment modalities: surgery, chemotherapy and radiotherapy. Its properties of activation with harmless physical agents (light and ultrasound), combined with its ability to generate cancer vaccines and stimulate an anti-cancer immune response warrant further development in a broad-spectrum oncology arena. With these results, the next development stage for SL052 is a Phase I clinical trial for the treatment of Prostate Cancer. Quest is presently awaiting approval from Health Canada that will allow it to initiate a Phase I clinical trial for SL052.

About Quest PharmaTech Inc.

Quest is a publicly traded, Alberta-based pharmaceutical company committed to the development and commercialization of new pharmaceutical products. It is developing a series of products for the treatment of cancer and dermatological conditions based on its unique photodynamic and sonodynamic therapy platforms.

    Neither TSX Venture Exchange nor its Regulation Services Provider (as
    that term is defined in the policies of the TSX Venture Exchange) accepts
    responsibility for the adequacy or accuracy of this release.


'/>"/>
SOURCE Quest PharmaTech Inc.
Copyright©2009 PR Newswire.
All rights reserved

Related biology technology :

1. ImmuneRegen Responds to Defense Threat Reduction Agency Request for Information
2. NovaQuest Advances Virtual Development Model With Strategic Investment in TOPIGEN Pharmaceuticals
3. Quest Diagnostics to Speak at the 2007 UBS Global Life Sciences Conference
4. VioQuest Pharmaceuticals to Present at BIO InvestorForum in San Francisco
5. Quest Diagnostics Joins National ePrescribing Patient Safety Initiative (NEPSI)
6. University HealthSystem Consortium Chooses SciQuest to Optimize Medical Research Procurement
7. VioQuest Pharmaceuticals to Present at the Paramount BioSciences Healthcare Conference
8. Sinovac Requests Extension for Annual Shareholders Meeting
9. Maryland Stem Cell Commission Issues Nationwide Request for Applications for New Post-Doctoral Fellowship Grants
10. AmSurg Selects SciQuest Eprocurement Solution to Automate Purchasing of Medical Goods and Services
11. Quest PharmaTech to Receive $3,000,000 to Develop Oncology Products Based on its SonoLight Technology
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:4/28/2016)... Rocky Hill, Conn. (PRWEB) , ... April 28, ... ... source of financing and ongoing support for Connecticut's innovative, growing companies, today announced ... early-stage digital health and financial technology (fintech) companies. , “VentureClash looks ...
(Date:4/27/2016)... ... 2016 , ... Cambridge Semantics, the leading provider of Smart Data ... has been named to The Silicon Review’s “20 Fastest Growing Big Data Companies of ... serves the needs of end users facing some of the most complex data challenges ...
(Date:4/27/2016)... , April 27, 2016 ... (CSE: NSK) (OTCPink: NSKQB) ( Frankfurt ... an ihre Pressemitteilung vom 13. August 2015 die ... ihre Finanzen um zusätzliche 200.000.000 Einheiten auf 400.000.000 ... Dollar zu bringen. Davon wurden 157.900.000 Einheiten mit ...
(Date:4/27/2016)... ... April 27, 2016 , ... PathSensors, Inc., a leading environmental ... Lamka will assist PathSensors in expanding the use of the company’s CANARY® technology ... test platform for the detection of harmful pathogens, including a number of bacteria, ...
Breaking Biology Technology:
(Date:4/15/2016)... CHICAGO , April 15, 2016  A ... companies make more accurate underwriting decisions in a ... offering timely, competitively priced and high-value life insurance ... health screenings. With Force Diagnostics, rapid ... and lifestyle data readings (blood pressure, weight, pulse, ...
(Date:3/31/2016)... Florida , March 31, 2016 ... ) ("LegacyXChange" or the "Company") LegacyXChange ... potential users of its soon to be launched online ... ( https://www.youtube.com/channel/UCyTLBzmZogV1y2D6bDkBX5g ) will also provide potential ... use of DNA technology to an industry that is ...
(Date:3/22/2016)... 2016 According to ... for Consumer Industry by Type (Image, Motion, Pressure, ... & IT, Entertainment, Home Appliances, & Wearable ... 2022", published by MarketsandMarkets, the market for ... USD 26.76 Billion by 2022, at a ...
Breaking Biology News(10 mins):